Kiniksa Pharmaceuticals (NASDAQ:KNSA) Issues Earnings Results, Misses Expectations By $0.11 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.11), Briefing.com reports. The firm had revenue of $79.90 million during the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The firm's revenue was up 65.4% on a year-over-year basis. During the same period last year, the business earned ($0.18) EPS.

Kiniksa Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ:KNSA traded up $0.18 during trading on Wednesday, reaching $17.86. The stock had a trading volume of 443,685 shares, compared to its average volume of 403,252. Kiniksa Pharmaceuticals has a 52 week low of $10.65 and a 52 week high of $22.09. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 99.23 and a beta of 0.27. The stock has a fifty day simple moving average of $19.36 and a two-hundred day simple moving average of $18.00.

Analysts Set New Price Targets

Several research firms have commented on KNSA. Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday. Wedbush restated an "outperform" rating and set a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. Finally, TheStreet upgraded shares of Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a report on Thursday, February 29th.

Insider Activity

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 5,582 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the sale, the chief executive officer now owns 65,012 shares in the company, valued at $1,365,252. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Sanj K. Patel sold 12,742 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the sale, the chief executive officer now owns 70,594 shares in the company, valued at approximately $1,517,065.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sanj K. Patel sold 5,582 shares of the business's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the completion of the sale, the chief executive officer now owns 65,012 shares in the company, valued at approximately $1,365,252. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock valued at $709,929 over the last 90 days. 54.23% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.